News

The Qiagen assay is designed to identify those patients whose tumors express the EGFRvIII mutation, allowing for the possibility of more targeted and personalised treatment. The company said

Currently, the most widely-used treatment for type 1 diabetes is the regular injection of insulin, a burdensome task for patients. Islet cell transplantation, whereby insulin-producing cells from a

The new drug application (NDA) for Zuplenz was accepted for review by the FDA in June 2009, and a response is expected in the first quarter of 2010

The company said that StarDrop 4.3 is the first major update to StarDrop, helping scientists to select high quality drug candidates thereby improving efficiency and productivity. StarDrop 4.3

The company said that the new SensiGene Fetal RhD Genotyping test is designed to detect circulating cell-free fetal (ccff) DNA from maternal blood and examine multiple regions of

Reported sales in the quarter increased 15% to $12.5 billion, compared to reported sales in the same period last year. EBITDA on a pro forma basis, excluding certain

Brentuximab Vedotin is an antibody-drug conjugate (ADC), currently in clinical trials for single-agent clinical trials, a pivotal trial for relapsed and refractory hodgkin lymphoma, and a phase II

Itochu acts in partnership with Optigenex under a long-term exclusive supply and trademark licensing agreement, to market AC-11 bulk material and consumer products containing AC-11 under sublicenses in

The company said that the new OC-Sensor Diana system measures 280 FIT samples per hour and ensures that quality data is consistently collected. In addition, its compact design